haloprogin

Trade name: halotex

Small moleculeapproved

Approved

Aug 6, 1971

Haloprogin is an active synthetic antifungal and antimonilial agent that was effective in the treatment of superficial fungal and monilial infections of the skin. Because of these two basic therapeutic effects, haloprogin was especially useful in the treatment of infections when the identity of the specific causative organism had not been established or is being determined. Studies in-vitro demonstrated antifungal, antimonilial and antibacterial activity. It was shown to demonstrate marked in-vitro activity against Staphylococcus and Streptococcus. Haloprogin is no longer available in the US. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1970s

  1. Aug 6, 1971

    Squibb — Earliest FDA Approval

  2. Aug 6, 1971

    Squibb — NDA Organization

Indications

Mechanism of action

  • Cell membraneINHIBITOR

    Cell membrane inhibitor

    Disrupts cell membrane

Approval history

  • approvedPriority reviewAug 6, 1971

Chemistry & pharmacology

Loading structure…

SMILES

ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
Mol. weight
361.391 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Discontinued

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • haloprogin
  • haloprogin
  • haloprogin
  • haloprogin
  • haloprogin
  • haloprogin
  • haloprogin
  • haloprogin
  • haloprogin
  • haloprogin
  • haloprogina
  • haloprogina
  • haloprogine
  • haloprogine
  • haloprogine
  • haloprogine
  • haloprogine
  • haloproginum
  • haloproginum
  • halotex
  • halotex
  • halotex
  • halotex
  • m-1028
  • m-1028
  • mycanden
  • mycanden
  • mycilan
  • théraplix brand of haloprogin
  • westwood squibb brand of haloprogin

Organizations

Marketing (1)

OrganizationOrg typeRelationshipDate
SquibbFor profitNDAAug 6, 1971